Financial Perspectives, Inc Nektar Therapeutics Transaction History

Financial Perspectives, Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 09, 2024	SELL	$10.83 - $18.41 $8,447 - $14,359	-780 Closed	0 $0
Q2 2021 Jan 09, 2024	SELL	$16.52 - $20.4 $244,826 - $302,328	-14,820 Reduced 95.0%	780 $13.4 Million
Q1 2021 Jan 09, 2024	BUY	$16.56 - $25.46 $245,419 - $377,317	14,820 Added 1900.0%	15,600 $780,000
Q4 2019 Jan 09, 2024	BUY	$15.87 - $23.12 $12,378 - $18,033	780 New	780 $16.8 Million

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Financial Perspectives, Inc, based on Form 13F filings with the SEC.

Stay updated on Financial Perspectives, Inc with notifications on news.